Desperate times call for desperate measures. Or in the case of Dutch conglomerate Akzo Nobel NV 's ailing human pharmaceuticals division, Organon NV , they call for Pfizer Inc. 's marketing muscle.
In late October 2003 Organon announced a worldwide co-promotion deal for its novel atypical antipsychotic asenapine, which is entering Phase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?